For the protection of frontline health care and emergency medical workers at high risk of infection, the U.S. Department of Labor's Occupational Safety and Health Administration (OSHA) today issued a compliance directive to ensure uniform procedures when conducting inspections to identify and minimize or eliminate high to very high risk occupational exposures to the 2009 H1N1 influenza A virus. [More]

Rates of infection by the 2009 H1N1 influenza virus may have peaked in late October, but the pandemic flu virus continues to be a potential source of illness in all age groups, including the elderly, according to a new report by Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services. [More]

RemedyMD (www.RemedyMD.com), the leading provider of disease registry software, today announced the first nationwide human immunology registry for infectious disease research. The new registry was developed to help clinicians and researchers better understand the human immune response to emerging and re-emerging infectious diseases. [More]

The deaths of 41 people from six countries who had received the H1N1 (swine flu) vaccine were not directly linked to the vaccine, the WHO said Thursday, the Associated Press/MSNBC reports (11/19). [More]

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets. [More]

Research and Markets (http://www.researchandmarkets.com/research/b6b2b6/monitoring_health) has announced the addition of Decision Resources, Inc.'s new report "Monitoring Health Through Novel Technologies: Where Are We with Point-of-Care Diagnostics?" to their offering. [More]

Only about 1 in 4 Americans aged 50-64 regularly take advantage of preventive services such as screenings and immunizations, according to a report from the Centers for Disease Control and Prevention in collaboration with AARP and the American Medical Association (AMA). [More]

Immunization with either live attenuated influenza vaccine (LAIV, also known as FluMist®), or trivalent inactivated influenza vaccine (TIV), appears to offer a protection (~ 45%) against the novel A/H1N1 virus, the cause of the present influenza pandemic. However, the benefit was largely attributed to the youngest age group. The finding emerges from an evaluation of medical encounters and seasonal influenza immunization of U.S. military service members. [More]

On November 19, 2009, the kick-off meeting for the Euregio-project "EurSafety Health-net" has taken place. EurSafety Health-net is the follow-up of EUREGIO MRSA-net, that, according to the Robert Koch Institute, gained some sort of model character all over the nation when talking about prevention of hospital acquired MRSA infection. Besides the protection against infection, the main goal of this new project is to strengthen the patients' safety on both sides of the border. [More]

A commentary in the December issue of The Lancet Infectious Diseases brings to light the gaps in knowledge on the transmission of a common pathogen - the influenza virus - and its impact on decisions about how best to protect health care workers. Infectious diseases specialist Leonard Mermel, DO, medical director of infection control for Rhode Island Hospital, looks at the ongoing debate in light of the H1N1 pandemic, what past research tells us about the spread of influenza, and what is missing in the debate. His commentary is currently available in an online first edition. [More]

BioCryst Pharmaceuticals, Inc. today announced the pricing of a public offering of 5,000,000 shares of its common stock at $9.75 per share, resulting in gross proceeds of $48.75 million. [More]

A new study on pediatric H1N1 influenza admissions has found that asthma is a significant risk factor for severe disease in children with pandemic H1N1 compared with the seasonal flu. [More]

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic. [More]

DxNA, a molecular diagnostics company headquartered in St. George, Utah, announced today that the DxNA GeneSTAT PCR system has successfully completed evaluation studies under the direction of a California laboratory supported by the Joint FAO/IAEA Programme in Food and Agriculture. [More]

Researchers at Yale School of Medicine have found that exaggerated responses of the immune system explain why the elderly succumb to viral infections more readily than younger people. Published in the November 19 Cell Host & Microbe, the study bucks the general belief that declining immune responses are to blame for susceptibility to viral infections. [More]